Articles with public access mandates - Paola GhioneLearn more
Available somewhere: 32
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast …
PG Cordeiro, P Ghione, A Ni, Q Hu, N Ganesan, N Galasso, A Dogan, ...
Journal of Plastic, Reconstructive & Aesthetic Surgery 73 (5), 841-846, 2020
Mandates: US National Institutes of Health
Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures
N Kotlov, A Bagaev, MV Revuelta, JM Phillip, MT Cacciapuoti, ...
Cancer discovery 11 (6), 1468-1489, 2021
Mandates: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR
D Drandi, L Kubiczkova-Besse, S Ferrero, N Dani, R Passera, B Mantoan, ...
The Journal of Molecular Diagnostics 17 (6), 652-660, 2015
Mandates: Government of Italy
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
S Ferrero, D Rossi, A Rinaldi, A Bruscaggin, V Spina, CW Eskelund, ...
haematologica 105 (6), 1604-1612, 2020
Mandates: Swiss National Science Foundation, Swiss Cancer League, Government of Italy …
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
AJ Moskowitz, P Ghione, E Jacobsen, J Ruan, JH Schatz, S Noor, ...
Blood, The Journal of the American Society of Hematology 138 (26), 2828-2837, 2021
Mandates: US National Institutes of Health
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
B Culjkovic-Kraljacic, TM Fernando, R Marullo, N Calvo-Vidal, A Verma, ...
Blood, The Journal of the American Society of Hematology 127 (7), 858-868, 2016
Mandates: US National Institutes of Health, Natural Sciences and Engineering Research …
AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis
M Teater, PM Dominguez, D Redmond, Z Chen, D Ennishi, DW Scott, ...
Nature communications 9 (1), 222, 2018
Mandates: US National Science Foundation, US National Institutes of Health, Lymphoma …
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
P Ghione, P Faruque, N Mehta-Shah, V Seshan, N Ozkaya, S Bhaskar, ...
Blood advances 4 (19), 4640-4647, 2020
Mandates: US National Institutes of Health
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
P Ghione, ML Palomba, AR Patel, S Bobillo, K Deighton, CA Jacobson, ...
Blood, The Journal of the American Society of Hematology 140 (8), 851-860, 2022
Mandates: US National Institutes of Health, Cancer Research UK
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
S Bobillo, E Joffe, JA Lavery, D Sermer, P Ghione, A Noy, PC Caron, ...
Blood, The Journal of the American Society of Hematology 137 (1), 39-48, 2021
Mandates: US National Institutes of Health
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
S Bobillo, E Joffe, D Sermer, P Mondello, P Ghione, PC Caron, ...
Blood cancer journal 11 (6), 1-6, 2021
Mandates: US National Institutes of Health
Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option?
P Mondello, N Steiner, W Willenbacher, S Ferrero, P Ghione, A Marabese, ...
The oncologist 21 (9), 1107-1112, 2016
Mandates: US National Institutes of Health
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
M Ladetto, S Ferrero, D Drandi, M Festuccia, F Patriarca, N Mordini, ...
Leukemia 30 (5), 1211-1214, 2016
Mandates: Government of Italy
Novel immunotherapies for T cell lymphoma and leukemia
P Ghione, AJ Moskowitz, NEK De Paola, SM Horwitz, M Ruella
Current hematologic malignancy reports 13, 494-506, 2018
Mandates: US National Institutes of Health
Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
AJ Moskowitz, P Ghione, ED Jacobsen, J Ruan, JH Schatz, S Noor, ...
Blood 134, 4019, 2019
Mandates: US National Institutes of Health
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population
P Ghione, S Qi, BS Imber, V Seshan, A Moskowitz, N Galasso, M Lunning, ...
Leukemia & lymphoma 61 (14), 3331-3341, 2020
Mandates: US National Institutes of Health
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
P Ghione, ML Palomba, H Ghesquieres, S Bobillo, AR Patel, M Nahas, ...
Haematologica 108 (3), 822, 2023
Mandates: US National Institutes of Health, Cancer Research UK
A novel JAK1 mutant breast implant-associated anaplastic large cell lymphoma patient-derived xenograft fostering pre-clinical discoveries
D Fiore, LV Cappelli, P Zumbo, JM Phillips, Z Liu, S Cheng, L Yoffe, ...
Cancers 12 (6), 1603, 2020
Mandates: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Novel immune-based treatments for diffuse large B-cell lymphoma: the post-CAR T cell era
SA Atallah-Yunes, MJ Robertson, UP Davé, P Ghione, F Perna
Frontiers in Immunology 13, 901365, 2022
Mandates: US National Institutes of Health, US Department of Veterans Affairs …
Publication and funding information is determined automatically by a computer program